

**Abstract Title:** Safety and Efficacy of Zanubrutinib in Patients With Relapsed/Refractory Marginal Zone Lymphoma (MAGNOLIA Phase 2 Study)

**Authors:** Stephen Opat<sup>1,2</sup>, Catherine Thieblemont<sup>3</sup>, Fontanet Bijou<sup>4</sup>, Emmanuel Bachy<sup>5</sup>, Régis Costello<sup>6</sup>, Alessandra Tedeschi<sup>7</sup>, Kim Linton<sup>8</sup>, Pamela McKay<sup>9</sup>, Bei Hu<sup>10</sup>, Pier Luigi Zinzani<sup>11</sup>, Morton Coleman<sup>12</sup>, Kirit Ardeshta<sup>13,14</sup>, Robert Marcus<sup>15</sup>, Craig Portell<sup>16</sup>, Roberto Marasca<sup>17</sup>, Federica Cavallo<sup>18</sup>, Anna Marina Liberati<sup>19</sup>, Sunil Iyengar<sup>20</sup>, Heidi Mociková<sup>21</sup>, Melannie Co<sup>22</sup>, Xiaotong Li<sup>22</sup>, Wenxiao Zhou<sup>22</sup>, Massimo Cappellini<sup>22</sup>, Chris Tankersley<sup>22</sup>, Jane Huang<sup>22</sup>, Judith Trotman<sup>23</sup>

**Affiliations:** <sup>1</sup>Monash Health, Clayton, Victoria, Australia; <sup>2</sup>Clinical Haematology Unit Monash University, Clayton, Victoria, Australia; <sup>3</sup>APHP, Hôpital Saint-Louis, Hemato-oncology, Paris University Diderot, Paris, France; ; <sup>4</sup>Institut Bergonié, Bordeaux, France; <sup>5</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, Rhone, Italy; <sup>6</sup>Hôpital de la Conception – APHM, Marseille, France; <sup>7</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; <sup>8</sup>The Christie, Manchester, UK; <sup>9</sup>Beatson West of Scotland Cancer Centre, Glasgow, UK; <sup>10</sup>Levine Cancer Institute/Atrium Health, Charlotte, NC, USA; <sup>11</sup>Institute of Hematology “Seràgnoli” University of Bologna, Bologna, Italy; <sup>12</sup>Clinical Research Alliance, Lake Success, NY, USA; <sup>13</sup>Department of Haematology, University College London NHS Foundation Trust, London, UK; <sup>14</sup>UCLH NIHR Biomedical Research Centre, London, UK; <sup>15</sup>Sarah Cannon Research Institute UK, London, UK; <sup>16</sup>University of Virginia Health System, Charlottesville, VA, USA; <sup>17</sup>AOU Policlinico di Modena, Modena, Italy; <sup>18</sup>Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy; <sup>19</sup>Azienda Ospedaliera Santa Maria Di Terni, Terni, Italy; <sup>20</sup>Royal Marsden Hospital, London, UK; <sup>21</sup>Fakultní nemocnice Královské Vinohrady, Praha 10, Czech Republic; <sup>22</sup>BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, USA; <sup>23</sup>Concord Repatriation General Hospital and University of Sydney, Concord, Australia

**Background:** Zanubrutinib is a potent, specific next-generation BTK inhibitor with higher selectivity for BTK compared with TEC- and EGFR-family kinases, which may be related to off-target toxicities.

**Aim/Objective:** The objective of this abstract is to present initial efficacy and safety results of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (R/R MZL) enrolled in the MAGNOLIA study (BGB-3111-214; NCT03846427).

**Methods:** In this single-arm, multicenter study, adults with R/R MZL who had received more than one prior therapy including at least one CD20 antibody regimen were treated with zanubrutinib 160 mg twice daily until disease progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR) by independent review committee (IRC). Secondary endpoints included investigator-assessed (INV) ORR, duration of response (DOR), progression-free survival (PFS), and safety.

**Results:** As of January 11, 2021, 68 patients were enrolled and treated. Median age was 70 years (range, 37-95) and 28% of patients were aged ≥75 years. Patients had the following MZL subtypes: extranodal (38%), nodal (38%), splenic (18%), and indeterminate (6%). Median number of prior therapies was 2 (range, 1-6), and 32% of patients had disease refractory to last therapy.

Median duration of drug exposure was 59.1 weeks (range, 3.7-84.1). At a median follow-up of 15.5 months (range, 1.6-21.7), INV ORR was 74% with a complete response rate of 24%. Responses were observed in all subtypes, with an ORR of 68%, 84%, 75%, and 50% in extranodal, nodal, splenic, and indeterminate subtypes, respectively. Median DOR and PFS were not reached. IRC review is ongoing.

Twenty-eight (41%) patients discontinued treatment (20 due to disease progression; 4 due to adverse events [AEs]). The most common treatment-emergent AEs reported in  $\geq 10\%$  of patients were diarrhea (22%), bruising (21%), and constipation (15%). Neutropenia was the most common grade  $\geq 3$  AE (10%). All-grade AEs of interest included neutropenia (13%), thrombocytopenia (13%), atrial fibrillation/flutter (3%), and hypertension (3%). AEs leading to treatment discontinuation included fatal Covid-19 pneumonia (n=2); fatal myocardial infarction in a patient with pre-existing coronary artery disease, and pyrexia attributed to disease transformation. No major/serious hemorrhage was reported. No AEs led to dose reductions.

**Conclusions:** Zanubrutinib demonstrated high response rates and durable disease control with a favorable safety profile in patients with R/R MZL.